RV
RVXCF.US Resverlogix Corp.
- Market cap
- USD 17.2M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RVXCF.US undervalued?
Graham numberThe Graham number of Resverlogix Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Resverlogix Corp. fundamental analysis
No fundamental analysis for Resverlogix Corp. yet.
Resverlogix Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Service…
Full company profileResverlogix Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Resverlogix Corp. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - | -331K | -438K | -323K |
| Operating Income | -34.1M | -30.9M | 85.6M | -23.0M | -13.0M | -16.0M | -12.7M | -6.21M | -4.65M | -5.20M | -5.62M |
| EBITDA | 377K | -30.5M | 86.0M | 1.03M | - | -14.9M | -11.7M | -14.2M | -4.25M | -4.77M | -5.30M |
| Net Income | -46.2M | -58.3M | -163M | 118M | 3.77M | -24.8M | -3.61M | -16.7M | -7.64M | -7.90M | -13.5M |
| EPS | -0.44 | -0.42 | -0.87 | 0.53 | - | -0.10 | -0.01 | -0.06 | -0.03 | -0.03 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 10.9M | 8.28M | 16.3M | 11.4M | - | 9.98M | 8.12M | 6.57M | 7.34M | 7.93M | 8.50M |
| Total Liabilities | 112M | 92.0M | 224M | 75.5M | - | 69.9M | 67.4M | 81.0M | 89.1M | 96.7M | 103M |
| Shareholders' Equity | -102M | -83.7M | -208M | -64.1M | - | -59.9M | -59.3M | -74.5M | -81.7M | -88.8M | -94.7M |
| Cash & Short-term Investments | 1.36M | 121K | 7.69M | 4.00K | - | 6.00K | 40.0K | 5.00K | 99.0K | 108K | 158K |
| Total Debt | 48.6M | 708K | 14.8M | 13.2M | - | 7.04M | 6.49M | - | 82.0M | 72.8M | 77.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -22.7M | -25.1M | -48.8M | -17.3M | -4.40M | -8.02M | -3.54M | -2.51M | -3.89M | -3.73M | -4.79M |
| Capital Expenditure | 559K | 537K | 622K | 500K | 394K | 877K | 450K | 448K | 472K | 9.16K | 415K |
| Free Cash Flow | -23.2M | -25.7M | -49.5M | -17.8M | -4.34M | -8.90M | -3.99M | -2.96M | -4.36M | -3.73M | -4.79M |
| Ratios | |||||||||||
| ROA | -425.2% | -704.4% | -999.6% | 1,037.3% | - | -248.2% | -44.5% | -255.0% | -104.0% | -99.6% | -158.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Resverlogix Corp. dividends
Resverlogix Corp. has not paid dividends in the last 9 fiscal years.
Who owns Resverlogix Corp.
- Insiders 26.36%
- Institutions 0.00%
- Public & others 73.64%
- Shares outstanding 344M
- Free float 251M
Resverlogix Corp. company profile
- Company name
- Resverlogix Corp.
- Ticker
- RVXCF.US
- ISIN
- CA76128M1086
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1
- Phone
- 403 254 9252
- Website
- resverlogix.com
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Resverlogix Corp. management
4- Mr. Donald J. McCaffreyCo-Founder, Chairman, President, CEO & Secretary
- Mr. Aaron Bradley Cann C.A., CPA, CBVChief Financial Officer
- Dr. Ewelina Kulikowski Ph.D.Chief Scientific Officer
- Dr. Michael Sweeney M.D.Senior Vice President of Clinical Development · born 1961